Cardiovagal Baroreflex Deficits Impair Neurovascular Coupling and Cognition in POTS
Postural Orthostatic Tachycardia Syndrome (POTS), POTS, Orthostatic Intolerance
About this trial
This is an interventional diagnostic trial for Postural Orthostatic Tachycardia Syndrome (POTS) focused on measuring Postural Orthostatic Tachycardia Syndrome (POTS), POTS, Orthostatic Intolerance, Digoxin, Pyridostigmine, Mestinon
Eligibility Criteria
Inclusion Criteria for POTS patients:
POTS patients referred for day to day orthostatic intolerance with greater than 3 symptoms for greater than 3 months and will have the diagnosis of symptomatic postural tachycardia made during a screening tilt table test :
- dizziness
- nausea and vomiting
- palpitations
- fatigue
- headache
- exercise intolerance
- blurred vision
- abnormal sweating heat.
Healthy control subjects:
- normal physical examination, and normal electrocardiographic and echocardiographic evaluations.
- Only those free from heart disease, and from systemic illness will be eligible to participate.
- This excludes patients with illnesses and disease states known to be associated with endothelial cell dysfunction such as diabetes, renal disease, congestive heart failure, systemic hypertension, acute and chronic inflammatory diseases, neoplasm, immune mediated disease, trauma, morbid obesity and peripheral vascular disease.
At the time of testing all patients and control subjects must refrain from vasoactive drugs for two weeks.
Exclusion Criteria for both POTS and healthy controls:
- An active medical condition that may explain the diagnosis
- A previous medical condition with undocumented resolution that may explain the diagnosis
- any systemic or overt structural, arrhythmic or myopathic cardiovascular disease
- any illnesses known to produce autonomic dysfunction such as diabetes, heart disease, renal disease, systemic hypertension, acute and chronic inflammatory diseases, neoplastic disease, immune mediated disease, major trauma and burns, morbid obesity and peripheral vascular disease will also be excluded.
- Cigarette smokers will be excluded.
- Past or present major psychiatric disorder
- Substance abuse within 2 years before onset of symptoms.
Sites / Locations
- New York Medical College/Bradhurst building
Arms of the Study
Arm 1
Arm 2
Active Comparator
Active Comparator
Pyridostigmine and Placebo
Digoxin and Placebo
Pyridostigmine 60mg by mouth one day and Placebo (Lactulose 50mg) by mouth on a different day
Digoxin 0.5mg (500mcg) by mouth one day and Placebo (Lactulose 50mg) by mouth on a different day